Endocrine Abstracts

Introduction: The aim of this study was to validate the American Thyroid Association (ATA) risk of recurrence staging system (2009).

Methods: Retrospective analysed 300 adult (239 women, 61 men) differentiated thyroid cancer patients followed for a median of 57 months (range 38–97).

Results: ATA risk stratification of patients according to the system 54.7% low-risk, 39.7% moderate risk, and 5.7% were in the high risk group. The responses of patients to treatment; 79.7% very well to treatment, 11% acceptable, 9.3% of the showed that the response is missing. In 21% of patients follow-up of persistent or recurrent disease in the last case was detected. Initial treatment responses based on the persistent structural or recurrent disease adapted risk estimation in low risk group not treated very well responsive 7.3% from 2.9%, intermediate-risk group and the treatment very good responders and 14.3% from 5.3%, higher risk group and 70.5% in those who respond very well to therapy than was seen in 60%. In this study the first 2 years treatment criteria follow-up of disease status of being considering the low risk group treated very well not respond, intermediate-risk group, stimulated thyroglobulin <1 ng/ml or treatment very good response of the high-risk group is suppressed Tg<1 ng/ml of being, at the end of follow-up showed that disease estimated to be more powerful.

Conclusion: According to ATA risk classification, initially recurrent/persistent disease was found to be a useful system to predict. However, only adapted to the risk of follow-up the patient’s entire life does not change during the initial risk estimates also showed that not be done. Tailored to each patient, to achieve dynamic and full of risk assessment, risk prediction system response to treatment is needed to conclude that the combination of the variables.